NutriBand Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by MELNIK SERGUEI, was filed 24 Feb 2022.
NutriBand Inc.: what insiders have been doing
NutriBand Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for NutriBand Inc. The previous disclosure was published on 8 March 2023.
Over the whole record (from 2017), the tally stands at 2 purchases and no sales. The 10-K for the year ended 31 January 2026 shows 2.0 m USD of revenue and -8.2 m USD of net income.
For comparison within the same sector, see the insider buying recorded at UCB. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Since the insiders bought
- +5.1%Entry US$3.56 · Close at T+365 US$3.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended January 2026 · cache
- 5,000 shares0Common Stock, par value $0.001 per shareSEC:0001213900-23-018365:0
- 10,000 shares0Common StockSEC:0001213900-22-037877:1
- 10,000 shares@ US$3.80100.0% of flowCommon StockSEC:0001213900-22-037877:0
- 500 shares@ US$4.039.1% of flowCommon Stock, par value $0.001 per shareSEC:0001213900-22-009240:0Canonical exit: 25 May 2022 (T+90)
- 5,000 shares@ US$4.0390.9% of flowCommon Stock, par value $0.001 per shareSEC:0001213900-22-009192:0Canonical exit: 25 May 2022 (T+90)
- 10,000 shares0Common Stock, par value $0.001 per shareSEC:0001213900-22-006347:0
- 20,000 shares0Common Stock, par value $0.001 per shareSEC:0001213900-19-009981:0
- 5,000 shares0Common Stock, par value $0.001 per shareSEC:0001213900-19-000322:0
- 1,000,000 shares0Common StockSEC:0001213900-17-008970:0
- 450,000 shares0Common StockSEC:0001213900-17-008972:0
10 of 10 declarations
About NutriBand Inc.
Nutriband Inc. is a U.S.-listed healthcare and pharmaceutical company traded on the NASDAQ in the United States. For investors, the company is best understood as a specialized transdermal drug-delivery developer with a strong focus on abuse-deterrent pharmaceutical technologies, especially in the context of the opioid crisis. Nutriband was incorporated in Nevada on January 4, 2016, and its operational headquarters are in Orlando, Florida. At this stage, the company is primarily a development-stage innovator rather than a broad commercial pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1676047/000121390026049399/ea0287168-10k_nutriband.htm?utm_source=openai))
The core investment case centers on AVERSA™, Nutriband’s transdermal technology platform designed to improve the safety profile of skin-delivered medicines, particularly fentanyl-based patch products. The company also works on broader transdermal pharmaceutical development through its clinical subsidiary 4P Therapeutics. In addition, Nutriband says it has revenue-generating subsidiaries, including Pocono Pharmaceutical, which focuses on contract manufacturing, and Active Intelligence, which is associated with sports recovery products. This gives the group a mixed profile that combines R&D, contract services, and early-stage commercial activity. ([nutriband.com](https://www.nutriband.com/?utm_source=openai))
Read moreShow less
Competitively, Nutriband operates in a niche but potentially attractive segment of the pharmaceutical industry: higher-value transdermal systems where differentiation depends on intellectual property, clinical evidence, regulatory progress, and the ability to secure industrial partners. The company’s strategic positioning is tied to abuse-deterrent solutions, a theme that can resonate with investors looking at specialty pharma and drug-delivery innovation. That said, the risk profile remains elevated because monetization still depends heavily on clinical, regulatory, and commercial execution. ([nasdaq.com](https://www.nasdaq.com/press-release/nutriband-unveils-groundbreaking-innovation-in-transdermal-medications-2023-09-20-0?utm_source=openai))
Recent developments reinforce the company’s pipeline-driven profile. In 2025, Nutriband said it received final meeting minutes from a U.S. FDA meeting regarding AVERSA™ FENTANYL, with the aim of supporting an IND submission for a Human Abuse Potential clinical study. Earlier disclosures also highlighted the issuance of a U.S. patent for AVERSA™ Technology and referenced commercial projections for its lead product. From an equity research perspective, Nutriband remains a NASDAQ-listed U.S. micro-cap story with identifiable regulatory catalysts, but limited visibility until more clinical and commercial milestones are achieved. ([nasdaq.com](https://www.nasdaq.com/press-release/nutriband-announces-successful-meeting-completed-united-states-fda-its-abuse?utm_source=openai))
